Pembrolizumab (pembro) vs. placebo as post nephrectomy adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study
Chairs: U. Capitanio, Milan (IT), P.F.A. Mulders, Nijmegen (NL)
Speaker: T. Powles, London (GB)Discussant: A. Breda, Barcelona (ES)